Bernd Misselwitz1, Johannes Platzek, Hanns-Joachim Weinmann. 1. Corporate Research Business Area Diagnostics and Radiopharmaceuticals, MRI and X-Ray Research, Schering, Müllerstrasse 178, D-13342 Berlin, Germany. bernd.misselwitz@schering.de
Abstract
PURPOSE: To investigate the dose and time dependency of gadofluorine M for lymph node imaging and the detection of lymph node metastases in an animal model and to compare gadofluorine M with Gadomer (both, Schering, Berlin, Germany) for lymph node enhancement. MATERIALS AND METHODS: Enhancement of popliteal and iliac lymph nodes was studied in VX2 tumor-bearing rabbits before injection and at 5-120 minutes and 24 hours after intravenous bolus injection of 0.025, 0.05, and 0.1 mmol gadolinium per kilogram of body weight gadofluorine M (six rabbits) or 0.5 mmol/kg Gadomer (eight rabbits). Effects of treatment and time point at enhancement were evaluated with repeated measures analysis of variance. Means were separated with all-pairs comparison with Tukey-Kramer adjustment. After 1.5-T magnetic resonance (MR) imaging, lymph nodes were removed, and prepared sections were stained with hematoxylin-eosin for microscopic examination. RESULTS: MR images in VX2 tumor-bearing rabbits revealed rapid and strong signal intensity increase in the functional lymph node tissue by 15 minutes after intravenous injection of gadofluorine M. Maximum enhancement of 165%-309% was observed 60-90 minutes after injection (enhancement with 0.05 and 0.1 mmol/kg significantly different from that with 0.025 mmol/kg, P < or =.05). Metastatic tissue showed only slight enhancement at early time points, resulting in high-contrast differentiation between functional and metastatic tissue. Intravenous injection of the blood-pool agent Gadomer induced only short and inhomogeneous lymph node enhancement (enhancement significantly lower [P < or =.05] than that with gadofluorine M). CONCLUSION: Findings in the study showed that gadofluorine M produces rapid lymph node accumulation. Diagnosis of lymph node metastases was shown with intravenous injection of gadofluorine M with a minimum effective diagnostic dose of 0.025 mmol/kg. Copyright RSNA, 2004
PURPOSE: To investigate the dose and time dependency of gadofluorine M for lymph node imaging and the detection of lymph node metastases in an animal model and to compare gadofluorine M with Gadomer (both, Schering, Berlin, Germany) for lymph node enhancement. MATERIALS AND METHODS: Enhancement of popliteal and iliac lymph nodes was studied in VX2 tumor-bearing rabbits before injection and at 5-120 minutes and 24 hours after intravenous bolus injection of 0.025, 0.05, and 0.1 mmol gadolinium per kilogram of body weight gadofluorine M (six rabbits) or 0.5 mmol/kg Gadomer (eight rabbits). Effects of treatment and time point at enhancement were evaluated with repeated measures analysis of variance. Means were separated with all-pairs comparison with Tukey-Kramer adjustment. After 1.5-T magnetic resonance (MR) imaging, lymph nodes were removed, and prepared sections were stained with hematoxylin-eosin for microscopic examination. RESULTS: MR images in VX2 tumor-bearing rabbits revealed rapid and strong signal intensity increase in the functional lymph node tissue by 15 minutes after intravenous injection of gadofluorine M. Maximum enhancement of 165%-309% was observed 60-90 minutes after injection (enhancement with 0.05 and 0.1 mmol/kg significantly different from that with 0.025 mmol/kg, P < or =.05). Metastatic tissue showed only slight enhancement at early time points, resulting in high-contrast differentiation between functional and metastatic tissue. Intravenous injection of the blood-pool agent Gadomer induced only short and inhomogeneous lymph node enhancement (enhancement significantly lower [P < or =.05] than that with gadofluorine M). CONCLUSION: Findings in the study showed that gadofluorine M produces rapid lymph node accumulation. Diagnosis of lymph node metastases was shown with intravenous injection of gadofluorine M with a minimum effective diagnostic dose of 0.025 mmol/kg. Copyright RSNA, 2004
Authors: Tobias D Henning; Olaf Saborowski; Daniel Golovko; Sophie Boddington; Jan S Bauer; Yanjun Fu; Reinhard Meier; Hubertus Pietsch; Barbara Sennino; Donald M McDonald; Heike E Daldrup-Link Journal: Eur Radiol Date: 2007-01-06 Impact factor: 5.315
Authors: Eric D Adler; Anne Bystrup; Karen C Briley-Saebo; Venkatesh Mani; Wilson Young; Steven Giovanonne; Perry Altman; Steven J Kattman; Joseph A Frank; Hans J Weinmann; Gordon M Keller; Zahi A Fayad Journal: JACC Cardiovasc Imaging Date: 2009-09
Authors: John A Ronald; Yuanxin Chen; Andre J-L Belisle; Amanda M Hamilton; Kem A Rogers; Robert A Hegele; Bernd Misselwitz; Brian K Rutt Journal: Circ Cardiovasc Imaging Date: 2009-03-24 Impact factor: 7.792
Authors: Hossein Nejadnik; Tobias D Henning; Thuy Do; Elizabeth J Sutton; Frederick Baehner; Andrew Horvai; Barbara Sennino; Donald McDonald; Reinhard Meier; Bernd Misselwitz; Thomas M Link; Heike E Daldrup-Link Journal: PLoS One Date: 2012-12-12 Impact factor: 3.240